Collectively, PPAR-γ agonists may exert neuroprotective effects by modulating the expression of genes in the cell survival pathway and the polarization of microglia, and may be a favorable target for the treatment of neurodegenerative diseases such as PD. This evidence concerns the gene PPARG and Parkinson disease.